Skip to main content
NIH funding notice RFA-DK-15-024

Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (T1D) (R43/R44)

Closed on November 18, 2015.

Posted
July 28, 2015
Close date
November 18, 2015
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $492,323 in first-year total cost, median $246,162.

Most frequent study sections

  1. Special Emphasis Panel[ZDK1 GRB-2 (M5)]2

Most frequent institutions

  1. ENABLE BIOSCIENCES, INC.1
  2. MIRNATECH INTERNATIONAL, INC.1
Competing awards under RFA-DK-15-024 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2016MiRNAs as serum biomarkers for T1D1R43DK111008-01PENG, HONGMEIZHOU, LIMIRNATECH INTERNATIONAL, INC., MI$267,900ZDK1
2016Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring1R43DK111005-01SEFTEL, DAVIDENABLE BIOSCIENCES, INC., CA$224,423ZDK1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.